Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 7/20 | 0.46 |
| ▸ | CDK1 | P06493 | 7/20 | 0.46 |
| ▸ | CCNB1 | P14635 | 7/20 | 0.46 |
| ▸ | JAK2 | O60674 | 6/20 | 0.40 |
| ▸ | JAK3 | P52333 | 4/20 | 0.40 |
| ▸ | FLT3 | P36888 | 2/20 | 0.40 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.39 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.38 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.38 |
| ▸ | CDK4 | P11802 | 1/20 | 0.37 |
| ▸ | CCND1 | P24385 | 1/20 | 0.37 |
| ▸ | CCND2 | P30279 | 1/20 | 0.37 |
| ▸ | CCND3 | P30281 | 1/20 | 0.37 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3587869 | 0.88 | CDK1 (0.47) | AURKACDK1CCNB1JAK2CDK2 | |
| SCHEMBL3580945 | 0.86 | AURKA (0.46) | AURKACDK1CCNB1JAK2JAK3 | |
| SCHEMBL3591405 | 0.85 | SYK (0.38) | AURKACDK1CCNB1JAK3FLT3 | |
| SCHEMBL3575913 | 0.82 | NPC1 (0.41) | AURKACDK1CCNB1JAK2JAK3 | |
| SCHEMBL3579094 | 0.81 | CDK4 (0.50) | AURKACDK1CCNB1JAK2JAK3 | |
| SCHEMBL3583463 | 0.80 | CDK4 (0.52) | AURKACDK1CCNB1JAK2JAK3 | |
| SCHEMBL3588130 | 0.77 | AURKA (0.39) | AURKACDK1CCNB1JAK2JAK3 | |
| SCHEMBL1353795 | 0.77 | DCLK1 (0.52) | AURKACDK1CCNB1FLT3DCLK1 | |
| SCHEMBL1356282 | 0.76 | FLT3 (0.52) | AURKACDK1CCNB1FLT3DCLK1 | |
| SCHEMBL1355460 | 0.73 | MARK3 (0.52) | AURKACDK1CCNB1JAK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100190787-A1 | Modulators of Mitotic Kinases | BIOGEN IDEC MA INC | 2010-07-29 | — | — | US | claimed |
| EP-2108019-A2 | 1-H-PYRAZOLO[3,4B]PYRIMIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF MITOTIC KINASES | Biogen Idec MA, Inc. (US) | 2009-10-14 | — | — | EP | claimed |
| WO-2008094575-A2 | 1-H-PYRAZOLO(3,4B)PYRIMIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF MITOTIC KINASES | BIOGEN IDEC MA INC. (US) | 2008-08-07 | — | — | WO | claimed |
| US-20100190787-A1 | Modulators of Mitotic Kinases | BIOGEN IDEC MA INC | 2010-07-29 | — | — | US | disclosed |
| EP-2108019-A2 | 1-H-PYRAZOLO[3,4B]PYRIMIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF MITOTIC KINASES | Biogen Idec MA, Inc. (US) | 2009-10-14 | — | — | EP | disclosed |
| WO-2008094575-A2 | 1-H-PYRAZOLO(3,4B)PYRIMIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF MITOTIC KINASES | BIOGEN IDEC MA INC. (US) | 2008-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190787-A1 | Modulators of Mitotic Kinases | CDK1, BUB1, BUB1B | AURKA 10/4885CDK1 1/4885CCNB1 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.